A GH Secretagogue Receptor Agonist (LUM-201) Elicits Greater GH Responses than Standard GH Secretagogues in Subjects of a Pediatric GH Deficiency Trial.

This study compared the growth hormone (GH) response elicited by a single oral dose of LUM-201 (ibutamoren/MK-0677), a GH secretagogue receptor agonist, to responses from standard diagnostic GH stimulation tests (arginine, glucagon, clonidine, L-dopa, and insulin-induced hypoglycemia) in 68 pediatric subjects enrolled in a pediatric growth hormone deficiency (PGHD) clinical trial. The study found that LUM-201 produced significantly greater GH responses than the conventional secretagogues, with median peak GH of 15.0 ng/mL versus 5.5 ng/mL for standard tests (p-value not fully captured in abstract but reported as statistically significant). Notably, the larger GH responses to LUM-201 were most pronounced in subjects who also showed higher peak GH responses to conventional testing, suggesting a functional somatotroph reserve may be required. The authors concluded that LUM-201 may represent a potential oral treatment alternative to injectable recombinant human GH (rhGH) in a subset of PGHD patients who demonstrate adequate acute GH responses to LUM-201. Limitations include the lack of a placebo-controlled design, relatively small sample size, and the single-dose comparison design which does not assess long-term growth outcomes.

Why this grade: The study is a non-randomized, non-placebo-controlled within-subject comparison in a small pediatric cohort (n=68), limiting causal inference and generalizability despite being conducted in humans.